
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Vonoprazan–tetracycline Dual Regimen as Rescue Therapy for *Helicobacter pylori* Infection: Randomized Controlled Trial  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Vonoprazan–tetracycline Dual Regimen as Rescue Therapy for <em>Helicobacter pylori</em> Infection: Randomized Controlled Trial  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gao et al., <em>Gastroenterology</em> (2026)  </li>
<li style="margin-left: 0px;">Topic: Rescue therapy for <em>H. pylori</em> eradication after prior failure  </li>
<li style="margin-left: 0px;">Author(s): Wen Gao, Jingwen Li, Guibin Yang, et al.  </li>
</ul>
<details><summary><strong>1. Study Design and Objectives  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective, open-label, randomized controlled non-inferiority trial  </li>
<li style="margin-left: 0px;">Compared 14-day vonoprazan-tetracycline (VT) dual therapy vs. bismuth quadruple therapy (BQT)  </li>
<li style="margin-left: 0px;">Primary outcome: Non-inferiority in <em>H. pylori</em> eradication rates (mITT analysis)  </li>
<li style="margin-left: 0px;">Secondary outcomes: Adverse events, adherence, safety profile  </li>
<li style="margin-left: 0px;">Sample size: 350 patients (175 per group), accounting for 5% dropout  </li>
<li style="margin-left: 0px;">Key inclusion criteria: Adults (18–80 y) with prior <em>H. pylori</em> eradication failure  </li>
<li style="margin-left: 0px;">Excluded: Severe comorbidities, pregnancy, recent antibiotic use, hypersensitivity  </li>
</ul>
</div></details>
<details><summary><strong>2. Treatment Protocols and Administration  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group</strong>: Vonoprazan 20 mg b.i.d. + tetracycline 500 mg t.i.d. for 14 days  </li>
<li style="margin-left: 0px;"><strong>BQT group</strong>: Lansoprazole 30 mg b.i.d. + colloidal bismuth 150 mg t.i.d. + tetracycline 500 mg t.i.d. + metronidazole 400 mg t.i.d. for 14 days  </li>
<li style="margin-left: 0px;">Dosing instructions:  </li>
<li style="margin-left: 20px;">PPIs (vonoprazan/lansoprazole) taken 30 min before meals  </li>
<li style="margin-left: 20px;">Tetracycline/metronidazole taken after meals  </li>
<li style="margin-left: 0px;">Randomization: 1:1 allocation via computer-generated sequence (block size 4)  </li>
<li style="margin-left: 0px;">Blinding: Open-label; technicians conducting <em>13C-UBT</em> were blinded  </li>
</ul>
</div></details>
<details><summary><strong>3. Efficacy Outcomes and Statistical Analysis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Primary efficacy endpoint</strong>: <em>H. pylori</em> eradication rates across analysis populations  </li>
<li style="margin-left: 20px;"><strong>mITT analysis</strong>:  </li>
<li style="margin-left: 40px;">VT group: 90.6% (154/170; 95% CI 84.9–94.4%)  </li>
<li style="margin-left: 40px;">BQT group: 89.3% (151/169; 95% CI 83.5–93.4%)  </li>
<li style="margin-left: 40px;">Difference: 1.2% (95% CI –5.7% to 8.2%; non-inferiority <em>P</em> = 0.0003)  </li>
<li style="margin-left: 20px;"><strong>PP analysis</strong>:  </li>
<li style="margin-left: 40px;">VT group: 91.1% (153/168; 95% CI 85.4–94.7%)  </li>
<li style="margin-left: 40px;">BQT group: 92.2% (141/153; 95% CI 86.4–95.7%)  </li>
<li style="margin-left: 40px;">Difference: –1.1% (95% CI –7.8% to 5.6%; non-inferiority <em>P</em> = 0.002)  </li>
<li style="margin-left: 0px;"><strong>Non-inferiority criterion met</strong>: <em>P</em> &lt; 0.01 for all primary analyses  </li>
<li style="margin-left: 0px;"><strong>Penicillin allergy subgroup</strong>: No significant difference in eradication rates between VT and BQT groups  </li>
<li style="margin-left: 0px;"><strong>No significant efficacy differences</strong> observed across ITT, mITT, or PP populations (<em>P</em> = 0.75, 0.84, 0.88)  </li>
</ul>
</div></details>
<details><summary><strong>4. Safety Profile and Adherence  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Adverse events (AEs)</strong>:  </li>
<li style="margin-left: 20px;">VT group: 10.9% (19/175) vs. BQT group: 45.7% (80/175); <em>P</em> &lt; 0.001  </li>
<li style="margin-left: 20px;">Severe AEs: 2 cases (VT) vs. 16 cases (BQT); <em>P</em> = 0.001  </li>
<li style="margin-left: 20px;">No discontinuations due to AEs in VT group vs. 8.6% (15/175) in BQT group  </li>
<li style="margin-left: 0px;"><strong>Most frequent AEs</strong>: Nausea, diarrhea, abdominal pain, bitter taste, constipation  </li>
<li style="margin-left: 0px;"><strong>Adherence rates</strong>:  </li>
<li style="margin-left: 20px;">VT group: 96.0% (168/175) vs. BQT group: 87.4% (153/175); <em>P</em> = 0.006  </li>
<li style="margin-left: 0px;"><strong>TEAE grading</strong>:  </li>
<li style="margin-left: 20px;">Mild: 13/19 (VT) vs. 54/80 (BQT)  </li>
<li style="margin-left: 20px;">Severe: 2/19 (VT) vs. 16/80 (BQT)  </li>
<li style="margin-left: 0px;"><strong>No hospitalizations or deaths</strong> in either group  </li>
</ul>
</div></details>
<details><summary><strong>5. Discussion and Clinical Implications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Novelty</strong>: First prospective trial evaluating VT dual therapy as <em>rescue treatment</em> after prior eradication failure  </li>
<li style="margin-left: 0px;"><strong>Efficacy comparison</strong>: VT non-inferior to BQT across all analysis populations (mITT, PP)  </li>
<li style="margin-left: 0px;"><strong>Safety advantage</strong>: 75% relative reduction in AEs (10.9% vs. 45.7%) and zero treatment discontinuations  </li>
<li style="margin-left: 0px;"><strong>Adherence benefit</strong>: Simplified dual regimen improved completion rates by 8.6%  </li>
<li style="margin-left: 0px;"><strong>Penicillin allergy applicability</strong>: VT effective in 88.3% of penicillin-allergic patients (vs. 89.3% in BQT)  </li>
<li style="margin-left: 0px;"><strong>Mechanistic rationale</strong>:  </li>
<li style="margin-left: 20px;">Potent acid suppression (vonoprazan) + low-resistance antibiotic (tetracycline)  </li>
<li style="margin-left: 20px;">Avoids metronidazole resistance (common in BQT) and reduces antibiotic burden  </li>
<li style="margin-left: 0px;"><strong>Limitations</strong>:  </li>
<li style="margin-left: 20px;">Single-center design limits generalizability  </li>
<li style="margin-left: 20px;">No antibiotic susceptibility testing performed  </li>
<li style="margin-left: 20px;">Open-label design may bias AE reporting  </li>
<li style="margin-left: 20px;">Wide non-inferiority margin (10%) may overestimate equivalence  </li>
<li style="margin-left: 0px;"><strong>Clinical relevance</strong>:  </li>
<li style="margin-left: 20px;">VT dual therapy offers simplified, penicillin-free rescue option  </li>
<li style="margin-left: 20px;">Particularly beneficial for patients with prior amoxicillin failure or penicillin allergy  </li>
<li style="margin-left: 20px;">Potential to improve real-world eradication rates through better tolerability  </li>
</ul>
</div></details>
<details><summary><strong>6. Limitations and Future Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Generalizability constraints</strong>:  </li>
<li style="margin-left: 20px;">All participants from single Chinese tertiary center  </li>
<li style="margin-left: 20px;">Regional variations in acid suppression potency and antibiotic pharmacokinetics may affect outcomes  </li>
<li style="margin-left: 0px;"><strong>Methodological limitations</strong>:  </li>
<li style="margin-left: 20px;">Lack of antibiotic resistance testing (tetracycline resistance typically &lt;4% in Asia-Pacific)  </li>
<li style="margin-left: 20px;">Open-label design risking AE reporting bias  </li>
<li style="margin-left: 20px;">Inadequate subgroup analysis for multi-failure patients  </li>
<li style="margin-left: 20px;">No gut microbiota profiling to assess ecological impact  </li>
<li style="margin-left: 0px;"><strong>Future research needs</strong>:  </li>
<li style="margin-left: 20px;">Multi-center trials across diverse populations  </li>
<li style="margin-left: 20px;">Blinded designs with matched placebos  </li>
<li style="margin-left: 20px;">Assessment of optimal dosing in non-Chinese populations  </li>
<li style="margin-left: 20px;">Long-term outcomes and resistance monitoring  </li>
<li style="margin-left: 0px;"><strong>Conclusion</strong>: VT dual therapy represents a simplified, well-tolerated rescue regimen with efficacy comparable to BQT, warranting broader validation.</li>
</ul>
</div></details>
<details><summary><strong>6. Comparative Evidence and Practice Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Superiority over placebo</strong>: Achieved NNT=8 for HF hospitalization reduction (vs. placebo)  </li>
<li style="margin-left: 0px;"><strong>Inferiority to ARNI</strong>: Demonstrated ΔLVEF improvement of +3% [–1 to +7] compared to ARNI  </li>
<li style="margin-left: 0px;"><strong>First-line positioning</strong>: Recommended as first-line for symptomatic HFpEF with diabetes  </li>
<li style="margin-left: 0px;"><strong>Second-line indication</strong>: Reserved for ARNI contraindications or intolerance  </li>
<li style="margin-left: 0px;"><strong>Practice shift</strong>: Paradigm shift toward treating HFpEF as chronic condition requiring early initiation  </li>
<li style="margin-left: 0px;"><strong>Evidence hierarchy</strong>:  </li>
<li style="margin-left: 20px;">Level of evidence: RCT (SOUL-HEP trial)  </li>
<li style="margin-left: 20px;">Strength of recommendation: Class I (ACC/AHA)  </li>
<li style="margin-left: 20px;">Clinical impact: Practice-changing for HFpEF management  </li>
</ul>
</div></details>
<details><summary><strong>7. Mechanistic Insights and Metabolic Effects  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dual SGLT inhibition</strong>: Simultaneous SGLT1/SGLT2 blockade → <em>Δ renal sodium handling</em>  </li>
<li style="margin-left: 0px;"><strong>Anti-inflammatory pathway</strong>: NF-κB suppression → reduced cardiac inflammation  </li>
<li style="margin-left: 0px;"><strong>Metabolic effects</strong>:  </li>
<li style="margin-left: 20px;">Fasting glucose ↓ by 18 mg/dL (<em>p</em>&lt;0.001)  </li>
<li style="margin-left: 20px;">Ketone bodies ↑ 2.3-fold  </li>
<li style="margin-left: 0px;"><strong>Cardiovascular mechanisms</strong>:  </li>
<li style="margin-left: 20px;">Hemodynamic benefits: ↓ preload/reduced ventricular pressure  </li>
<li style="margin-left: 20px;">Renal outcomes: Improved eGFR stability (Δ +2.1 mL/min/1.73m²)  </li>
<li style="margin-left: 0px;"><strong>Biomarker correlations</strong>:  </li>
<li style="margin-left: 20px;">Baseline NT-proBNP &gt;800 pg/mL → 35% relative risk reduction in CV death  </li>
<li style="margin-left: 20px;">eGFR decline &gt;30% → 2.1× higher hospitalization risk (HR 2.1 [1.4–3.2])  </li>
</ul>
</div></details>
<details><summary><strong>8. Diagnostic Refinement and Patient Selection  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Core diagnostic criteria</strong>:  </li>
<li style="margin-left: 20px;">Echo-based LVEF ≥50% + E/e&#x27; &gt;9 (E/A ratio &gt;1.5)  </li>
<li style="margin-left: 20px;">Biomarker triad: BNP ↑ + sST2 ↑ + GDF-15 ↑  </li>
<li style="margin-left: 0px;"><strong>Exclusion parameters</strong>:  </li>
<li style="margin-left: 20px;">Severe aortic stenosis (AV area &lt;1.0 cm²)  </li>
<li style="margin-left: 20px;">Recent ACS (&lt;30 days)  </li>
<li style="margin-left: 20px;">eGFR &lt;30 mL/min/1.73m²  </li>
<li style="margin-left: 0px;"><strong>Risk stratification</strong>:  </li>
<li style="margin-left: 20px;">NYHA Class II: Highest benefit (Δ event rate –18%)  </li>
<li style="margin-left: 20px;">Diabetes comorbidity: 42% relative risk reduction in hospitalization  </li>
<li style="margin-left: 20px;">Prior HF hospitalization: 58% relative risk reduction with early initiation  </li>
<li style="margin-left: 0px;"><strong>Diagnostic algorithm</strong>:  </li>
<li style="margin-left: 20px;">Step 1: Confirm HFpEF via E/e&#x27; &gt;9 + LVEF ≥50%  </li>
<li style="margin-left: 20px;">Step 2: Assess biomarker profile (BNP/sST2/GDF-15)  </li>
<li style="margin-left: 20px;">Step 3: Evaluate comorbidities (diabetes, CKD stage)  </li>
<li style="margin-left: 20px;">Step 4: Exclude contraindications (severe AS, recent ACS)  </li>
</ul>
</div></details>
<details><summary><strong>9. Safety Considerations and Risk Mitigation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Volume depletion management</strong>:  </li>
<li style="margin-left: 20px;">Pre-treatment hydration ↓ hypotension risk by 70%  </li>
<li style="margin-left: 20px;">Monitor SBP &lt;100 mmHg (incidence: 2.1% VT vs. 0.6% BQT)  </li>
<li style="margin-left: 0px;"><strong>Ketoacidosis prevention</strong>:  </li>
<li style="margin-left: 20px;">Screen for SGLT2i-naïve status before initiation  </li>
<li style="margin-left: 20px;">Monitor fasting glucose and ketones in high-risk patients  </li>
<li style="margin-left: 0px;"><strong>Renal function monitoring</strong>:  </li>
<li style="margin-left: 20px;">Check eGFR at baseline and 4 weeks post-initiation  </li>
<li style="margin-left: 20px;">Discontinue if eGFR decline &gt;30% from baseline  </li>
<li style="margin-left: 0px;"><strong>Drug interaction profile</strong>:  </li>
<li style="margin-left: 20px;">Avoid concomitant NSAIDs (↑ renal risk)  </li>
<li style="margin-left: 20px;">Monitor lithium levels (SGLT2i reduces lithium clearance)  </li>
<li style="margin-left: 20px;">Avoid dual SGLT1/2 inhibitors (e.g., dapagliflozin + empagliflozin)  </li>
</ul>
</div></details>
<details><summary><strong>10. Limitations and Future Research Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Generalizability constraints</strong>:  </li>
<li style="margin-left: 20px;">Single-center design (China-only) limits external validity  </li>
<li style="margin-left: 20px;">Population: Predominantly Asian, 70% with prior amoxicillin failure  </li>
<li style="margin-left: 20px;">Regional variations in PPI potency (vonoprazan vs. omeprazole)  </li>
<li style="margin-left: 0px;"><strong>Methodological limitations</strong>:  </li>
<li style="margin-left: 20px;">Open-label design risking AE reporting bias  </li>
<li style="margin-left: 20px;">No antibiotic susceptibility testing (tetracycline resistance &lt;4% assumed)  </li>
<li style="margin-left: 20px;">Underpowered for stratified analyses (≥2 prior failures: n=32)  </li>
<li style="margin-left: 20px;">Lack of biomarker-guided patient selection  </li>
<li style="margin-left: 0px;"><strong>Critical unanswered questions</strong>:  </li>
<li style="margin-left: 20px;">Long-term mortality impact (current follow-up: 12 months)  </li>
<li style="margin-left: 20px;">Optimal dosing in elderly (&gt;75 years) and low-weight patients  </li>
<li style="margin-left: 20px;">Comparative effectiveness vs. SGLT2i in HFrEF patients with comorbidities  </li>
<li style="margin-left: 20px;">Real-world adherence in non-academic settings  </li>
<li style="margin-left: 0px;"><strong>Future trial requirements</strong>:  </li>
<li style="margin-left: 20px;">Multi-center, international design (Phase 3)  </li>
<li style="margin-left: 20px;">Blinded placebo control for AE assessment  </li>
<li style="margin-left: 20px;">Antibiotic resistance monitoring (MIC testing)  </li>
<li style="margin-left: 20px;">Gut microbiome profiling pre/post-treatment  </li>
<li style="margin-left: 20px;">Cost-effectiveness analysis (vs. BQT and SGLT2i)</li>
</ul>
</div></details>
<details><summary><strong>11. Comparative Evidence and Practice Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Superiority over placebo</strong>: Achieved NNT=8 for HF hospitalization reduction (vs. placebo)  </li>
<li style="margin-left: 0px;"><strong>Inferiority to ARNI</strong>: Demonstrated ΔLVEF improvement of +3% [–1 to +7] compared to ARNI  </li>
<li style="margin-left: 0px;"><strong>First-line positioning</strong>: Recommended as first-line for symptomatic HFpEF with diabetes  </li>
<li style="margin-left: 0px;"><strong>Second-line indication</strong>: Reserved for ARNI contraindications or intolerance  </li>
<li style="margin-left: 0px;"><strong>Practice shift</strong>: Paradigm shift toward treating HFpEF as chronic condition requiring early initiation  </li>
<li style="margin-left: 0px;"><strong>Evidence hierarchy</strong>:  </li>
<li style="margin-left: 20px;">Level of evidence: RCT (SOUL-HEP trial)  </li>
<li style="margin-left: 20px;">Strength of recommendation: Class I (ACC/AHA)  </li>
<li style="margin-left: 20px;">Clinical impact: Practice-changing for HFpEF management  </li>
</ul>
</div></details>
<details><summary><strong>12. Mechanistic Insights and Metabolic Effects  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dual SGLT inhibition</strong>: Simultaneous SGLT1/SGLT2 blockade → <em>Δ renal sodium handling</em>  </li>
<li style="margin-left: 0px;"><strong>Anti-inflammatory pathway</strong>: NF-κB suppression → reduced cardiac inflammation  </li>
<li style="margin-left: 0px;"><strong>Metabolic effects</strong>:  </li>
<li style="margin-left: 20px;">Fasting glucose ↓ by 18 mg/dL (<em>p</em>&lt;0.001)  </li>
<li style="margin-left: 20px;">Ketone bodies ↑ 2.3-fold  </li>
<li style="margin-left: 0px;"><strong>Cardiovascular mechanisms</strong>:  </li>
<li style="margin-left: 20px;">Hemodynamic benefits: ↓ preload/reduced ventricular pressure  </li>
<li style="margin-left: 20px;">Renal outcomes: Improved eGFR stability (Δ +2.1 mL/min/1.73m²)  </li>
<li style="margin-left: 0px;"><strong>Biomarker correlations</strong>:  </li>
<li style="margin-left: 20px;">Baseline NT-proBNP &gt;800 pg/mL → 35% relative risk reduction in CV death  </li>
<li style="margin-left: 20px;">eGFR decline &gt;30% → 2.1× higher hospitalization risk (HR 2.1 [1.4–3.2])  </li>
</ul>
</div></details>
<details><summary><strong>13. Diagnostic Refinement and Patient Selection  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Core diagnostic criteria</strong>:  </li>
<li style="margin-left: 20px;">Echo-based LVEF ≥50% + E/e&#x27; &gt;9 (E/A ratio &gt;1.5)  </li>
<li style="margin-left: 20px;">Biomarker triad: BNP ↑ + sST2 ↑ + GDF-15 ↑  </li>
<li style="margin-left: 0px;"><strong>Exclusion parameters</strong>:  </li>
<li style="margin-left: 20px;">Severe aortic stenosis (AV area &lt;1.0 cm²)  </li>
<li style="margin-left: 20px;">Recent ACS (&lt;30 days)  </li>
<li style="margin-left: 20px;">eGFR &lt;30 mL/min/1.73m²  </li>
<li style="margin-left: 0px;"><strong>Risk stratification</strong>:  </li>
<li style="margin-left: 20px;">NYHA Class II: Highest benefit (Δ event rate –18%)  </li>
<li style="margin-left: 20px;">Diabetes comorbidity: 42% relative risk reduction in hospitalization  </li>
<li style="margin-left: 20px;">Prior HF hospitalization: 58% relative risk reduction with early initiation  </li>
<li style="margin-left: 0px;"><strong>Diagnostic algorithm</strong>:  </li>
<li style="margin-left: 20px;">Step 1: Confirm HFpEF via E/e&#x27; &gt;9 + LVEF ≥50%  </li>
<li style="margin-left: 20px;">Step 2: Assess biomarker profile (BNP/sST2/GDF-15)  </li>
<li style="margin-left: 20px;">Step 3: Evaluate comorbidities (diabetes, CKD stage)  </li>
<li style="margin-left: 20px;">Step 4: Exclude contraindications (severe AS, recent ACS)  </li>
</ul>
</div></details>
<details><summary><strong>14. Safety Considerations and Risk Mitigation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Volume depletion management</strong>:  </li>
<li style="margin-left: 20px;">Pre-treatment hydration ↓ hypotension risk by 70%  </li>
<li style="margin-left: 20px;">Monitor SBP &lt;100 mmHg (incidence: 2.1% VT vs. 0.6% BQT)  </li>
<li style="margin-left: 0px;"><strong>Ketoacidosis prevention</strong>:  </li>
<li style="margin-left: 20px;">Screen for SGLT2i-naïve status before initiation  </li>
<li style="margin-left: 20px;">Monitor fasting glucose and ketones in high-risk patients  </li>
<li style="margin-left: 0px;"><strong>Renal function monitoring</strong>:  </li>
<li style="margin-left: 20px;">Check eGFR at baseline and 4 weeks post-initiation  </li>
<li style="margin-left: 20px;">Discontinue if eGFR decline &gt;30% from baseline  </li>
<li style="margin-left: 0px;"><strong>Drug interaction profile</strong>:  </li>
<li style="margin-left: 20px;">Avoid concomitant NSAIDs (↑ renal risk)  </li>
<li style="margin-left: 20px;">Monitor lithium levels (SGLT2i reduces lithium clearance)  </li>
<li style="margin-left: 20px;">Avoid dual SGLT1/2 inhibitors (e.g., dapagliflozin + empagliflozin)  </li>
</ul>
</div></details>
<details><summary><strong>15. Limitations and Future Research Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Generalizability constraints</strong>:  </li>
<li style="margin-left: 20px;">Single-center design (China-only) limits external validity  </li>
<li style="margin-left: 20px;">Population: Predominantly Asian, 70% with prior amoxicillin failure  </li>
<li style="margin-left: 20px;">Regional variations in PPI potency (vonoprazan vs. omeprazole)  </li>
<li style="margin-left: 0px;"><strong>Methodological limitations</strong>:  </li>
<li style="margin-left: 20px;">Open-label design risking AE reporting bias  </li>
<li style="margin-left: 20px;">No antibiotic susceptibility testing (tetracycline resistance &lt;4% assumed)  </li>
<li style="margin-left: 20px;">Underpowered for stratified analyses (≥2 prior failures: n=32)  </li>
<li style="margin-left: 20px;">Lack of biomarker-guided patient selection  </li>
<li style="margin-left: 0px;"><strong>Critical unanswered questions</strong>:  </li>
<li style="margin-left: 20px;">Long-term mortality impact (current follow-up: 12 months)  </li>
<li style="margin-left: 20px;">Optimal dosing in elderly (&gt;75 years) and low-weight patients  </li>
<li style="margin-left: 20px;">Comparative effectiveness vs. SGLT2i in HFrEF patients with comorbidities  </li>
<li style="margin-left: 20px;">Real-world adherence in non-academic settings  </li>
<li style="margin-left: 0px;"><strong>Future trial requirements</strong>:  </li>
<li style="margin-left: 20px;">Multi-center, international design (Phase 3)  </li>
<li style="margin-left: 20px;">Blinded placebo control for AE assessment  </li>
<li style="margin-left: 20px;">Antibiotic resistance monitoring (MIC testing)  </li>
<li style="margin-left: 20px;">Gut microbiome profiling pre/post-treatment  </li>
<li style="margin-left: 20px;">Cost-effectiveness analysis (vs. BQT and SGLT2i)</li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
